Baseline comparison of SSc-patients with and without anti-Ro/SSA antibodies.
| Patients with anti-Ro/SSA antibodies (n=641) | Patients without anti-Ro/SSA antibodies (n=3580) | P value | |
|---|---|---|---|
| Age | 56.4±13.9 | 55.2±13.9 | 0.056 |
| Female sex | 556 (86.7%) | 2996 (83.7%) | 0.059 |
| Disease duration | 7.0±7.4 | 7.5±8.5 | 0.233 |
| Extent of skin involvement • Sine scleroderma • Diffuse cutaneous • Limited cutaneous | 24 (11.7%) 56 (27.2%) 126 (61.2%) | 126 (10.3%) 329 (27.0%) 765 (62.7%) | 0.834 |
| Joint contracture | 90 (14.7%) | 635 (18.4%) | 0.034 |
| Muscular involvement* | 103 (18.0%) | 414 (12.5%) | <0.001 |
| CRP >10 mg/L | 24 (4.6%) | 117 (4.1%) | 0.64 |
| Digital Ulcers • Current or previous • Never | 224 (38.2%) 362 (61.8%) | 1249 (33.7%) 2066 (62.3%) | 0.888 |
| Dyspnea NYHA > II | 15 (7.4%) | 73 (6%) | 0.892 |
| Lung fibrosis on HRCT | 286 (56.2%) | 1260 (47.8%) | 0.001 |
| FVC in patients with lung fibrosis | 85.2±22.0 | 85.2±22.0 | 0.992 |
| DLCO in patients with lung fibrosis | 59.0±18.6 | 61.9±20.2 | 0.041 |